MHRA’s Tallon on the tall order of boosting the U.K. as a destination for clinical trials

On the cusp of his one-year anniversary as CEO of MHRA, Lawrence Tallon is about to see what may become a signature development come into force, and what he and others hope will be the start of a new era for the U.K. life science sector.

Tallon became head of the U.K. regulatory agency on April 1, 2025. On April 28, 2026, the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 will come into effect, a move the government calls the most significant overhaul of U.K. clinical trial regulations in 20 years...